Index. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.

Size: px

Start display at page:

Download "Index. derm.theclinics.com. Note: Page numbers of article titles are in boldface type."

Kristina Cameron
5 years ago
Views:

1 Note: Page numbers of article titles are in boldface type. A Acitretin and cutaneous T-cell lymphomas, , 722, 725 ADCC. See Antibody-dependent cell-mediated cytotoxicity. Adjunctive therapies and extracorporeal photopheresis, 770, 771 Adjuvant therapies with total skin electron beam therapy, 708, 709 AECTCL. See Aggressive epidermotropic cytotoxic T-cell lymphoma. Aggressive epidermotropic cytotoxic T-cell lymphoma, 665, 666 ALCL. See Anaplastic large cell lymphoma. Alemtuzumab, 829 Alitretinoin and cutaneous T-cell lymphomas, 692 Alkyl sulfonates Alkylating agents and cutaneous T-cell lymphomas, Allogeneic stem cell transplantation and cutaneous T-cell lymphomas, , and mycosis fungoides, 829 Anaplastic large cell lymphoma and anti-cd30, 779, 780 Anthracyclines 797 Anti-CC chemokine receptor 4 and cutaneous T-cell lymphomas, 781, 782 Anti-CD4 and cutaneous T-cell lymphomas, 781 Anti-CD25 and cutaneous T-cell lymphomas, 780, 781 Anti-CD30 and anaplastic large cell lymphoma, 779, 780 and cutaneous T-cell lymphomas, and lymphomatoid papulosis, 779 lymphoma, 779 Anti-CD52 and cutaneous T-cell lymphomas, 778, 779 Antibodies in clinical practice, Antibody-dependent cell-mediated cytotoxicity and monoclonal antibodies, 777, 778, 781, 782 Dermatol Clin 33 (2015) /15/$ see front matter Ó 2015 Elsevier Inc. All rights reserved. Anti cytotoxic T-lymphocyte antigen 4 and cutaneous T-cell lymphomas, 782, 783 Antifolates and cutaneous T-cell lymphomas, 793 Anti killer cell immunoglobulin-like receptor 3DL2 and cutaneous T-cell lymphomas, 782 Antimetabolites and cutaneous T-cell lymphomas, Apoptosis and folate antagonists, 748, 749 ASCT. See Autologous hematopoietic stem cell transplantation. Autologous hematopoietic stem cell transplantation and cutaneous T-cell lymphomas, 808, 810, 811, 814, 815 B BCNU. See Bichlorethylnitrosourea. Belinostat and peripheral T-cell lymphomas, 761, 762 Bendamustine Bexarotene and cutaneous T-cell lymphomas, 692, , and lymphomatoid papulosis, 822, 823 side effects of, 724 Bichlorethylnitrosourea and cutaneous T-cell lymphomas, 689, 690 Biologic response modifiers and cutaneous T-cell lymphomas, 715, 716 Bone marrow transplantation. See Hematopoietic stem cell transplantation. Bortezomib and cutaneous T-cell lymphomas, 799 Brentuximab vedotin lymphoma, 825 BRM. See Biologic response modifiers. Busulfan C Carboplatin derm.theclinics.com

2 842 Carmustine and cutaneous T-cell lymphomas, 689, 690, 795 CBCL. See Cutaneous B-cell lymphoma. CD30 1 lymphoproliferative disorders and folate antagonists, 748, 752 management of, radiation therapy for, Checkpoint blockade inhibitors and cutaneous T-cell lymphomas, 782, 783 Chemotherapeutic agents and cutaneous T-cell lymphomas, with interferon alfa therapy, 738, 739 and mycosis fungoides, and Sézary syndrome, Chlorambucil and cutaneous T-cell lymphomas, 793, 794 Chronic lymphocytic leukemia and monoclonal antibodies, 778, 782 Cisplatin Cladribine and cutaneous T-cell lymphomas, 791 Clinicopathologic correlation and cutaneous lymphomas, 655, 657, 658, 660, , 667 CLL. See Chronic lymphocytic leukemia. Corticosteroids and cutaneous T-cell lymphomas, 684, 685 and lymphomatoid papulosis, 821 CTCL. See Cutaneous T-cell lymphoma. Cutaneous B-cell lymphomas, , 650, 653 diagnosis of, 653, 836 and Epstein-Barr virus associated B-cell lymphoproliferations, evaluation of, 653 incidence of, 653 and intravascular large B-cell lymphoma, 673 and primary cutaneous diffuse large B-cell, other, 672, 673 and primary cutaneous diffuse large B-cell lymphoma, leg type, 672 and primary cutaneous follicle center lymphoma, 671, 672 and primary cutaneous marginal zone lymphoma, and response assessment, 653 staging of, 653, 836 Cutaneous lymphomas classification of, 644 and clinicopathologic correlation, 655, 657, 658, 660, , 667 diagnosis of, epidemiology of, and genotyping, 657 and lymphomatoid papulosis, and mycosis fungoides, , pathologic diagnosis of, and phenotyping, 657 primary, 643, 644, 652, 653 and Sézary syndrome, , 659, 660 subtypes of, Cutaneous peripheral T-cell lymphoma, unspecified, 667 Cutaneous T-cell lymphomas, , 650, 652 and acitretin, , 722, 725 and alitretinoin, 692 and alkyl sulfonates, 795 and alkylating agents, and allogeneic stem cell transplantation, , and anthracyclines, and anti-cc chemokine receptor 4, 781, 782 and anti-cd4, 781 and anti-cd25, 780, 781 and anti-cd30, and anti-cd52, 778, 779 and antibodies in clinical practice, and anti cytotoxic T-lymphocyte antigen 4, 782, 783 and antifolates, 793 and anti killer cell immunoglobulin-like receptor 3DL2, 782 and antimetabolites, and bendamustine, 794 and bexarotene, 692, , and bichlorethylnitrosourea, 689, 690 and biologic response modifiers, 715, 716 and bortezomib, 799 and busulfan, 795 and carboplatin, 795 and carmustine, 689, 690, 795 and checkpoint blockade inhibitors, 782, 783 and chemotherapeutic agents, and chlorambucil, 793, 794 and cisplatin, 795 and cladribine, 791 combination therapy for, 748, 749 and corticosteroids, 684, 685 and cutaneous CD4 1 small/medium-sized T-cell lymphoma, 664, 665 and cutaneous peripheral T-cell lymphoma, unspecified, 667 and cyclophosphamide, 794 and cytosine arabinoside, 792 and dacarbazine, 795 and daunorubicin, 796 and doxorubicin, 796 emerging topical therapies for, 692 and emollients, 684 and epirubicin, 796 and ethylenimines, 795

3 843 and etoposide, 797 and extracorporeal photopheresis, and extranodal natural killer/t-cell lymphoma, nasal type, 667 and fludarabine, 791 and 5-fluorouracil, 792 and folate antagonists, and forodesine, 798, 799 and gemcitabine, 792, histone deacetylase inhibitors for, and idrarubicin, 797 and ifosfamide, 794 and interferon alfa, and interferon beta, 741 and interferon gamma, 740, 741 interferons in, and interleukin-2, 797, 798 and interleukin-12, 798 and interleukins, 797, 798 and IPH4102, 782 and ipilimumab, 782, 783 and isotretinoin, , and LMB-2, 782 and lomustine, 794 and mechlorethamine, , 793 and melphalan, 794 and 6-mercaptopurine, 791 and metal salts, 795 and methotrexate, and mogamulizumab, 781, 782 and monoclonal antibodies, and monoclonal antibodies in clinical trials, 781, 782 and multiagent chemotherapy, , 799 and myeloablative conditioning, 809, and nimustine, 705 and nitrogen mustards, and nitrosoureas, 795 and nivolumab, 783 and panobinostat, 762 and pembrolizumab, 783 and pentostatin, 791, 792 and peripheral T-cell lymphoma, 664 and photochemotherapy, and pralatrexate, and primary cutaneous anaplastic large T-cell lymphoma, 663, 664 and primary cutaneous CD8 1 aggressive epidermotropic cytotoxic T-cell lymphoma, 665, 666 and primary cutaneous g/d T-cell lymphoma, 666, 667 and procarbazine, 795 and programmed death-1, 783 and proteasome inhibitors, 799 and purine analogs, and purine nucleoside phosphorylase inhibitors, 798, 799 and pyrimidine analogs, 792, 793 radiation therapy for, and reduced-intensity conditioning, and retinoic acid receptors, , 724, 725, 727 and retinoic X receptors, , 724, 725, 727 retinoids for, and rexinoids, , 720, 721, and romidepsin, 760, 761 skin-directed therapies for, and subcutaneous panniculitis-like T-cell lymphoma, 664 and systemic retinoids, and tazarotene, 692 and temozolomide, 795 and thiotepa, 795 topical chemotherapeutics for, topical therapies for, and topoisomerase inhibitors, and triazines, 795 and vorinostat, and zanolimumab, 781 Cyclophosphamide Cytosine arabinoside and cutaneous T-cell lymphomas, 792 D Dacarbazine Daunorubicin and cutaneous T-cell lymphomas, 796 DC. See Dendritic cells. Dendritic cells and extracorporeal photopheresis, 766, 767, 773 Diagnosis and management of cutaneous B-cell lymphoma, Dihydrofolate reductase folate antagonist inhibition of, 747, 748, 750 DLI. See Donor lymphocyte infusion. DNA methyltransferase methotrexate depletion of, , 753 DNMT. See DNA methyltransferase. Donor lymphocyte infusion 809, 810, 812, 814, 815 Doxorubicin and cutaneous T-cell lymphomas, 796

4 844 E EBV. See Epstein-Barr virus. ECP. See Extracorporeal photopheresis. Emollients and cutaneous T-cell lymphomas, 684 EORTC. See European Organization for Research and Treatment of Cancer. Epirubicin and cutaneous T-cell lymphomas, 796 Epstein-Barr virus associated B-cell lymphoproliferations, Erythrodermic cutaneous T-cell lymphomas and extracorporeal photopheresis, 769, 770 Erythrodermic disease and total skin electron beam therapy, 708 Ethylenimines Etoposide and cutaneous T-cell lymphomas, 797 European Organization for Research and Treatment of Cancer and CTCLs and CBCLs, , 651, 652 guidelines for total skin electron beam therapy, 709 Evaluation, diagnosis, and staging of cutaneous lymphoma, Excision lymphoma, 825 Extracorporeal photopheresis and adjunctive therapies, 770, 771 adverse effects of, 771 and cutaneous T-cell lymphomas, and dendritic cells, 766, 767, 773 in early stage CTCL, 768, 769 in erythrodermic CTCL, 769, 770 historical aspects of, 765, 766 with interferon alfa therapy, 738 mechanism of action of, 766, 767 and mycosis fungoides, pharmacokinetics of, 767 and predictors of response, 771, 772 and response to therapy, 768 and Sézary syndrome, and survival rates, 771 and total skin electron beam radiotherapy, 769 in tumor stage CTCL, 769 typical regimen of, 767, 768 Extracorporeal photopheresis in the treatment of mycosis fungoides and Sézary syndrome, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, treatment of, 837, 838 Extranodal natural killer/t-cell lymphoma, nasal type, 667 F FAS expression and folate antagonists, 747, 749, 751, 752 Fludarabine and cutaneous T-cell lymphomas, Fluorouracil and cutaneous T-cell lymphomas, 792 Folate antagonists adverse effects of, 753 and apoptosis, 748, 749 and CD30 1 lymphoproliferative disorders, 748, 752 and cutaneous T-cell lymphomas, and dihydrofolate reductase inhibition, 747, 748, 750 dosing of, 750 and FAS expression, 747, 749, 751, 752 and folic acid, 747, 748, 750, 752 and gene expression, 747, 748 indications for, 748 and lymphomatoid papulosis, 748, 750, 752, 753 mechanism of action of, 748, 749 and mycosis fungoides, pharmacokinetics of, 749, 750 and purine synthesis, 747, 748 and response to therapy, and S phase, 748, 753 and Sézary syndrome, and thymidylate synthesis, 748 Folic acid and folate antagonists, 747, 748, 750, 752 Forodesine and cutaneous T-cell lymphomas, 798, 799 G Gemcitabine and cutaneous T-cell lymphomas, 792, 793 Gene expression and folate antagonists, 747, 748 Graft-versus-host disease Graft-versus-lymphoma effect 810, 811, 814, 815 GVHD. See Graft-versus-host disease. GvL. See Graft-versus-lymphoma.

5 845 H Hand/foot psoralen plus ultraviolet A and mycosis fungoides, 699 HDAC. See Histone deacetylase. Hematopoietic stem cell transplant for mycosis fungoides and Sézary syndrome, Hematopoietic stem cell transplantation autologous, 808, 810, 811, 814, 815 complications of, 809, 810 and conditioning regimens, 809 and cutaneous T-cell lymphomas, and donor lymphocyte infusion, 809, 810, 812, 814, 815 and donor selection, 808, 809 and graft-versus-host disease, and graft-versus-lymphoma effect, 810, 811, 814, 815 and mycosis fungoides, and Sézary syndrome, and stem cell sources, 808 Histone deacetylase inhibitors chemical structure of, 759 and cutaneous T-cell lymphomas, mechanism of action of, 757, 758 and mycosis fungoides, for peripheral T-cell lymphomas, 757, 758, and Sézary syndrome, Histone deacetylase inhibitors for cutaneous T-cell lymphoma, HL. See Hodgkin lymphoma. Hodgkin lymphoma and monoclonal antibodies, 779, 780, 782 Human nuclear receptors and ligands, 716 I Idrarubicin and cutaneous T-cell lymphomas, 797 IFN. See Interferon. Ifosfamide Imiquimod and lymphomatoid papulosis, 823 Interferon alfa adverse effects of, 739 with chemotherapeutics, 738, 739 and cutaneous T-cell lymphomas, dosing of, 733, 734 with extracorporeal photopheresis, 738 mechanism of action of, 732 in multimodality treatment, 739 with oral retinoids, 738 pharmacokinetics of, 732, 733 and psoralen plus ultraviolet A phototherapy, 737 and response to therapy, with total skin electron beam therapy, 738 Interferon beta and cutaneous T-cell lymphomas, 741 Interferon gamma adverse effects of, 741 in combination treatment, 740, 741 and cutaneous T-cell lymphomas, 740, 741 dosing of, 740 mechanism of action of, 740 pharmacokinetics of, 740 and response to therapy, 740, 741 Interferons in cutaneous T-cell lymphoma therapy, and lymphomatoid papulosis, 823 and mycosis fungoides, , and Sézary syndrome, , Interleukin-2 and cutaneous T-cell lymphomas, 797, 798 Interleukin-12 and cutaneous T-cell lymphomas, 798 Interleukins and cutaneous T-cell lymphomas, 797, 798 International Society for Cutaneous Lymphomas and CTCLs and CBCLs, , 651, 652 Intravascular large B-cell lymphoma, 673 IPH4102 and cutaneous T-cell lymphomas, 782 Ipilimumab and cutaneous T-cell lymphomas, 782, 783 ISCL. See International Society for Cutaneous Lymphomas. Isotretinoin and cutaneous T-cell lymphomas, , side effects of, 724 L LMB-2 and cutaneous T-cell lymphomas, 782 Lomustine Lymphoid neoplasms World Health Organization classification for, 656 Lymphomatoid papulosis, 650, 652 and anti-cd30, 779 and bexarotene, 822, 823 differential diagnosis, and folate antagonists, 748, 750, 752, 753 histology of, and imiquimod, 823 and interferon, 823

6 846 Lymphomatoid (continued) and methotrexate, 822 and nitrogen mustard, 823 and phototherapy, 821, 822 radiation therapy for, 711 skin responses in, 652 subtypes of, 821 and topical corticosteroids, 821 treatment of, Lymphoproliferative disorders CD30 1, 660, , 748, 752, classification of, 651 diagnosis of, 650 evaluation of, incidence of, 650 and lymphomatoid papulosis, 650, 652 lymphoma, 650, 652 prognosis of, 650 and response assessment, 652 staging of, LyP. See Lymphomatoid papulosis. M mab. See Monoclonal antibodies. MAC. See Myeloablative conditioning. Mechlorethamine and cutaneous T-cell lymphomas, , 793 Melphalan 6-Mercaptopurine and cutaneous T-cell lymphomas, 791 Metal salts Methotrexate and cutaneous T-cell lymphomas, and DNA methyltransferase depletion, , 753 and lymphomatoid papulosis, 822 lymphoma, 825 and S-adenosyl methionine reduction, Methotrexate and pralatrexate, MF. See Mycosis fungoides. Mogamulizumab and cutaneous T-cell lymphomas, 781, 782 Monoclonal antibodies, and antibody-dependent cell-mediated cytotoxicity, 777, 778, 781, 782 and chronic lymphocytic leukemia, 778, 782 classification of, 778 in clinical trials, 781, 782 and cutaneous T-cell lymphomas, and Hodgkin lymphoma, 779, 780, 782 and mycosis fungoides, and Sézary syndrome, MTX. See Methotrexate. Multiagent chemotherapy and cutaneous T-cell lymphomas, , 799 Mycosis fungoides and alemtuzumab, 828, 829 and allogeneic stem cell transplantation, 829 and bexarotene, 828 and brentuximab vedotin, 828 and chemotherapeutic agents, classification of, 647 and clonality, 658 and combination therapies, 829 diagnosis of, 645, 646 and differential diagnosis, 658, 659 evaluation of, and extracorporeal photopheresis, extracorporeal photopheresis in early stage, 768, 769 extracorporeal photopheresis in tumor stage, 769 and folate antagonists, and gemcitabine, 828 and genetics, 658 global response scores in, 649 and hand/foot psoralen plus ultraviolet A, histology of, 657, 658 and histone deacetylase inhibitors, and immunophenotype, 658 and interferon treatment, , with large cell transformation, and local radiation therapy, and monoclonal antibodies, and pegylated liposomal doxorubicin, 828 phototherapy of, and pralatrexate, 827, 828 and psoralen plus ultraviolet A therapy, 698, 699 and response assessment, 649 and romidepsin, 828 skin-directed therapies for, , 687, skin responses in, 649 staging of, and systemic retinoids, , and T-cell receptor gene rearrangement, 645, 646, 648 and total skin electron beam therapy, treatment of, and ultraviolet B phototherapy, 697, 698 variants of, 659 Myeloablative conditioning and cutaneous T-cell lymphomas, 809, N Nimustine and cutaneous T-cell lymphomas, 705

7 847 Nitrogen mustards and cutaneous T-cell lymphomas, and lymphomatoid papulosis, 823 Nitrosoureas Nivolumab and cutaneous T-cell lymphomas, 783 O Other chemotherapeutic agents in cutaneous T-cell lymphoma, P Panobinostat and cutaneous T-cell lymphomas, 762 Pathologic diagnosis of cutaneous lymphoma, PCALCL. See Primary cutaneous anaplastic large cell lymphoma. PCDLBCL. See Primary cutaneous diffuse large B-cell lymphoma. PCFCL. See Primary cutaneous follicle center lymphoma. PCGD-TCL. See Primary cutaneous g/d T-cell lymphoma. PCL. See Primary cutaneous lymphoma. PCMZL. See Primary cutaneous marginal zone lymphoma. PD-1. See Programmed death-1. PDX. See Pralatrexate. Pembrolizumab and cutaneous T-cell lymphomas, 783 Pentostatin and cutaneous T-cell lymphomas, 791, 792 Peripheral T-cell lymphomas, 664 and belinostat, 761, 762 histone deacetylase inhibitors for, 757, 758, and romidepsin, 760, 761 Photochemotherapy and cutaneous T-cell lymphomas, Phototherapy and lymphomatoid papulosis, 821, 822 Phototherapy of mycosis fungoides, efficacy of, 698, 699 safety of, 699, 700 treatment schedules for, 698 Practical management of CD30 1 lymphoproliferative disorders, Pralatrexate and cutaneous T-cell lymphomas, and mycosis fungoides, 827, 828 Primary cutaneous anaplastic large cell lymphoma, 650, 652 and anti-cd30, 779 and brentuximab vedotin, 825 and combination therapies, 826 and etoposide, 826 and excision, 825 and gemcitabine, 826 global disease response scores in, 652 and imiquimod, 826 and interferon, 826 and methotrexate, 825 and phototherapy, 826 radiation therapy for, 711, 712 and radiotherapy, 825 and retinoids, 825, 826 treatment of, Primary cutaneous anaplastic large T-cell lymphoma, 663, 664 Primary cutaneous diffuse large B-cell lymphoma, leg type, 837, 838 and clonality, 672 and differential diagnosis, 672 and genetics, 672 histology of, 672 and immunophenotype, 672 treatment of, 838 Primary cutaneous diffuse large B-cell lymphoma, other, 672, 673 Primary cutaneous follicle center lymphoma, and clonality, 671 and differential diagnosis, 671, 672 and genetics, 671 histology of, 671 and immunophenotype, 671 treatment of, 837, 838 Primary cutaneous g/d T-cell lymphoma, 666, 667 Primary cutaneous lymphoma, 643, 644, 652, 653 and Surveillance, Epidemiology, and End Results registry, 643, 644 Primary cutaneous marginal zone lymphoma, and clonality, 670 and differential diagnosis, 670, 671 and genetics, 670 histology of, and immunophenotype, 670 Procarbazine Programmed death-1 and cutaneous T-cell lymphomas, 783 Proteasome inhibitors and cutaneous T-cell lymphomas, 799 Psoralen and mycosis fungoides, Psoralen plus ultraviolet A with interferon alfa, 737

8 848 Psoralen (continued ) and mycosis fungoides, PTCL. See Peripheral T-cell lymphomas. Purine analogs and cutaneous T-cell lymphomas, Purine nucleoside phosphorylase inhibitors and cutaneous T-cell lymphomas, 798, 799 Purine synthesis and folate antagonists, 747, 748 PUVA. See Psoralen plus ultraviolet A. Pyrimidine analogs and cutaneous T-cell lymphomas, 792, 793 R Radiation therapy for cutaneous T-cell lymphomas, Radiation therapy for mycosis fungoides outcomes of, 704 and palliation of individual lesions, 704, 705 and palliation of nodal and visceral disease, 705 side effects of, 705 in stage IA disease, 704 technique for, Radiotherapy lymphoma, 825 RAR. See Retinoic acid receptors. Reduced-intensity conditioning and cutaneous T-cell lymphomas, Retinoic acid receptors and cutaneous T-cell lymphomas, , 724, 725, 727 Retinoic X receptors and cutaneous T-cell lymphomas, , 724, 725, 727 Retinoids for cutaneous T-cell lymphomas, with interferon alfa therapy, 738 lymphoma, 825, 826 Rexinoids and cutaneous T-cell lymphomas, , 720, 721, RIC. See Reduced-intensity conditioning. The role of systemic retinoids in the treatment of cutaneous T-cell lymphoma, Romidepsin and cutaneous T-cell lymphomas, 760, 761 and peripheral T-cell lymphomas, 760, 761 RT. See Radiation therapy. RXR. See Retinoic X receptors. S S-adenosyl methionine methotrexate reduction of, S phase and folate antagonists, 748, 753 SAM. See S-adenosyl methionine. SEER. See Surveillance, Epidemiology, and End Results registry. Sézary syndrome and chemotherapeutic agents, classification of, 647 diagnosis of, 645 evaluation of, and extracorporeal photopheresis, and folate antagonists, global response scores in, and histone deacetylase inhibitors, and interferon treatment, , and monoclonal antibodies, and response assessment, 649 skin-directed therapies for, skin responses in, 649 staging of, and systemic retinoids, 716, , Skin-directed therapies in cutaneous T-cell lymphoma, Small/medium-sized T-cell lymphoma, 664, 665 SMTL. See Small/medium-sized T-cell lymphoma. SPTCL. See Subcutaneous panniculitis-like T-cell lymphoma. SS. See Se zary syndrome. Stem cell transplantation and total skin electron beam therapy, 709 Subcutaneous panniculitis-like T-cell lymphoma and clonality, 664 and differential diagnosis, 664 histology of, 664 and immunophenotype, 664 Surveillance, Epidemiology, and End Results registry and primary cutaneous lymphoma, 643, 644 Systemic retinoids adverse effects of, 724, 726 and cutaneous T-cell lymphomas, mechanism of action of, 716 monitoring patients on, 726 and mycosis fungoides, , and Sézary syndrome, 716, , T T-cell receptor gene rearrangement in mycosis fungoides, 645, 646, 648 Tazarotene and cutaneous T-cell lymphomas, 692 TCR GR. See T-cell receptor gene rearrangement. Temozolomide

9 849 Thiotepa Thymidylate synthesis and folate antagonists, 748 Topical chemotherapeutics for cutaneous T-cell lymphomas, Topical therapies for cutaneous T-cell lymphomas, Topoisomerase inhibitors 797 Total skin electron beam radiotherapy and extracorporeal photopheresis, 769 Total skin electron beam therapy with interferon alfa, 738 Total skin electron beam therapy for mycosis fungoides with adjuvant therapies, 708, 709 in advanced stage disease, 708 dose of, in early stage disease, 707, 708 EORTC guidelines for, 709 in erythrodermic disease, 708 in retreatment, 708 side effects of, 711 before stem cell transplantation, 709 technique of, 709 treatment positions for, 710 Triazines TSEBT. See Total skin electron beam therapy. U Ultraviolet A therapy and mycosis fungoides, Ultraviolet B phototherapy and mycosis fungoides, U.S. Cutaneous Lymphoma Consortium and CTCLs and CBCLs, , 652 USCLC. See U.S. Cutaneous Lymphoma Consortium. The use of interferons in the treatment of cutaneous T-cell lymphoma, UVA. See Ultraviolet A. UVB. See Ultraviolet B. V Vorinostat and cutaneous T-cell lymphomas, W World Health Organization classification for Lymphoid neoplasms, 656 Z Zanolimumab and cutaneous T-cell lymphomas, 781

Therapeutic Management of Early Cutaneous Mycosis Fungoides

Therapeutic Management of Early Cutaneous Mycosis Fungoides L Frank Glass, MD Cutaneous Lymphoma Programs H Lee Moffitt Cancer Center and Research Institute George Washington University Dermatology and